• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

PERTUZUMAB Drug Record

  • Summary
  • Interactions
  • Claims
  • PERTUZUMAB chembl:CHEMBL2007641 ApprovedAntineoplastic

    Alternate Names:

    PERTUZUMAB
    PERJETA
    OMNITARG
    OMNITARG PERJETA
    RHUMAB-2C4
    RG-1273
    MOAB 2C4
    MONOCLONAL ANTIBODY 2C4
    2C4 ANTIBODY
    chemidplus:380610-27-5
    drugbank:06366
    chembl:CHEMBL2007641
    rxcui:1298944

    Drug Info:

    FDA Approval not approved
    Drug Class monoclonal antibody
    Drug Indications antineoplastic agent
    FDA Approval Breast cancer (HER2+)
    Drug Class Therapeutic Antibodies
    (9 More Sources)

    Publications:

    Franklin et al., 2004, Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex., Cancer Cell
    Yarlagadda B et al., 2019, Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma., NPJ Precis Oncol
    Meric-Bernstam F et al., 2019, Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study., Lancet Oncol
    Hainsworth JD et al., 2018, Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study., J Clin Oncol
    Baselga et al., 2012, Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer., N. Engl. J. Med.
    Swain et al., 2015, Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer., N. Engl. J. Med.
    Blumenthal et al., 2013, First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer., Clin. Cancer Res.
    Martin et al., 2016, Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study., Ann. Oncol.
    Kodack et al., 2017, The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation., Sci Transl Med
    Bertotti et al., 2011, A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer., Cancer Discov
    Hanker et al., 2013, Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies., Proc. Natl. Acad. Sci. U.S.A.
    Jaiswal et al., 2013, Oncogenic ERBB3 mutations in human cancers., Cancer Cell
    Thomas et al., 2014, HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models., Oncotarget
    Capparelli et al., 2015, ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas., Cancer Res.
    Heining C et al., 2018, <i>NRG1</i> Fusions in <i>KRAS</i> Wild-Type Pancreatic Cancer., Cancer Discov
  • PERTUZUMAB   ERBB3

    Interaction Score: 1.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Variant Effect gain-of-function
    Pathway activation
    Clinical Status preclinical

    PMIDs:
    23680147 25216528 26206558


    Sources:
    DoCM CIViC

  • PERTUZUMAB   ERBB2

    Interaction Score: 1.16

    Interaction Types & Directionality:
    antibody (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Notes Prevents dimerization of HER2 with other HER receptors
    combination therapy Trastuzumab + Pertuzumab
    Indication/Tumor Type Her2-receptor positive breast cancer

    PMIDs:
    15093539 31453370 30857956 29320312 22149875 25693012 23801166 27052654 28539475 22586653 23940356


    Sources:
    TALC ClearityFoundationBiomarkers MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions CIViC PharmGKB TTD FDA OncoKB

  • PERTUZUMAB   NRG1

    Interaction Score: 0.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29802158


    Sources:
    CIViC

  • PERTUZUMAB   PGR

    Interaction Score: 0.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • PERTUZUMAB   BRAF

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29320312


    Sources:
    CIViC

  • PERTUZUMAB   ESR2

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • PERTUZUMAB   PIK3CA

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy BKM120 + Trastuzumab + Pertuzumab
    Indication/Tumor Type Her2-receptor positive breast cancer
    Response Type sensitive

    PMIDs:
    23940356


    Sources:
    JAX-CKB

  • PERTUZUMAB   ESR1

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • MyCancerGenome: PERTUZUMAB

    • Version: 20-Jun-2017

    Alternate Names:
    MOAB2C4 Development Name
    PERTUZUMAB Generic Name
    PERJETA Trade Name

    Drug Info:
    Drug Class Therapeutic Antibodies
    FDA Approval Breast cancer (HER2+)

    Publications:

  • TdgClinicalTrial: PERTUZUMAB

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class monoclonal antibody
    FDA Approval not approved

    Publications:

  • DoCM: PERTUZUMAB

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Jaiswal et al., 2013, Oncogenic ERBB3 mutations in human cancers., Cancer Cell

  • JAX-CKB: Pertuzumab

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Bertotti et al., 2011, A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer., Cancer Discov
    Blumenthal et al., 2013, First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer., Clin. Cancer Res.
    Hanker et al., 2013, Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies., Proc. Natl. Acad. Sci. U.S.A.

  • CIViC: PERTUZUMAB

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Hainsworth JD et al., 2018, Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study., J Clin Oncol
    Yarlagadda B et al., 2019, Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma., NPJ Precis Oncol
    Baselga et al., 2012, Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer., N. Engl. J. Med.

  • TALC: PERTUZUMAB

    • Version: 12-May-2016

    Alternate Names:
    PERTUZUMAB Primary Drug Name
    PERTUZUMAB Drug Generic Name
    PERJETA Drug Trade Name

    Drug Info:

    Publications:

  • TTD: Pertuzumab

    • Version: 2020.06.01

    Alternate Names:
    D0CI4E TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL2007641

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • OncoKB: Pertuzumab

    • Version: 23-July-2020

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationBiomarkers: PERTUZUMAB

    • Version: 26-July-2013

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL2007641

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Pertuzumab

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

  • PharmGKB: pertuzumab

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21